While epilepsy and encephalopathy are common among patients with pathogenic variants in DNM1L, there are also reports of peripheral neuropathy in some patients with heterozygous mutations in the GTPase domains [219,221,234]. Here, DNM1L is linked to peripheral neuropathy.